ISG12a mediates cell response to Newcastle disease viral infection

Virology

Volumn 462-463, Issue 1, 2014, Pages 283-294

  Liu, Nianli ^a,b   Long, Ying ^a   Liu, Bin ^a   Yang, Darong ^a   Li, Chen ^a   Chen, Tianran ^a   Wang, Xiaohong ^a   Liu, Chen ^c   Zhu, Haizhen ^a,b  

^a HUNAN UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Innate immunity; ISG12a; Liver cancer; Newcastle disease virus

Indexed keywords

BETA INTERFERON; CASPASE 3; CASPASE 7; CASPASE 9; INTERFERON RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN NOXA; PUMA PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; ISG12A GENE; LIVER CELL CARCINOMA; MALE; MOUSE; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS REPLICATION;

INNATE IMMUNITY; ISG12A; LIVER CANCER; NEWCASTLE DISEASE VIRUS;

CELLS, CULTURED; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 84903762141     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.06.014     Document Type: Article

References (38)

1. Altomonte J., Marozin S., Schmid R.M., Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 2010, 18:275-284.
2. Cary Z.D., Willingham M.C., Lyles D.S. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J. Virol. 2011, 85:5708-5717.
3. Cheriyath V., Leaman D.W., Borden E.C. Emerging roles of FAM14 family members in innate immunity and cancer. J. Interferon Cytokine Res. 2011, 31:173-181.
4. Elankumaran S., Rockemann D., Samal S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006, 80:7522-7534.
5. Fiola C., Peeters B., Fournier P., Arnold A., Bucur M., Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer 2006, 119:328-338.
6. Fournier P., Wilden H., Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int. J. Oncol. 2012, 40:287-298.
7. Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 2006, 13:221-228.
8. Goldsmith K.C., Gross M., Peirce S., Luyindula D., Liu X., Vu A., Sliozberg M., Guo R., Zhao H., Reynolds C.P., Hogarty M.D. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 2012, 72:2565-2577.
9. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2011, 10:561-574.
10. Hu B., Nandhu M.S., Sim H., Agudelo-Garcia P.A., Saldivar J.C., Dolan C.E., Mora M.E., Nuovo G.J., Cole S.E., Viapiano M.S. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 2012, 72:3873-3885.
11. Huang P.Y., Guo J.H., Hwang L.H. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol. Ther. 2012, 20:298-305.
12. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
13. Lazar I., Yaacov B., Shiloach T., Eliahoo E., Kadouri L., Lotem M., Perlman R., Zakay-Rones Z., Panet A., Ben-Yehuda D. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J. Virol. 2010, 84:639-646.
14. Lorence R.M., Scot Roberts M., ONeil J.D., Groene W.S., Miller J.A., Mueller S.N., Bamat M.K. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 2007, 7:157-167.
15. Mansour M., Palese P., Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 2011, 85:6015-6023.
16. Matsumura Y., Yashiro M., Ohira M., Tabuchi H., Hirakawa K. 5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells. Anticancer Res. 2005, 25:3271-3278.
17. Meng S., Zhou Z., Chen F., Kong X., Liu H., Jiang K., Liu W., Hu M., Zhang X., Ding C., Wu Y. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett. 2012, 317:56-64.
18. Park M.S., Garcia-Sastre A., Cros J.F., Basler C.R., Palese P. Newcastle disease virus V protein is a determinant of host range restrict. J. Virol. 2003, 77:9522-9532.
19. Puhlmann J., Puehler F., Mumberg D., Boukamp P., Beier R. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 2010, 29(15):2205-2216.
20. Rosebeck S., Leaman D.W. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis 2008, 13:562-572.
21. Shi S., Yu X., Gao Y., Xue B., Wu X., Wang X., Yang D., Zhu H. Inhibition of hepatitis C virus production by aptamer for core protein. J. Virol. 2014, 88:1990-1999.
22. Shobana R., Samal S.K., Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol. 2013, 87:3792-3800.
23. Smith W., Tomasec P., Aicheler R., Loewendorf A., NemčovičováI I., Wang E.C., Stanton R.J. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe. 2013, 13:324-335.
24. Smyth M.J. Type I interferon and cancer immunoediting. Nat. Immunol. 2005, 6:646-648.
25. Sun Y., Leaman D.W. Involvement of Noxa in cellular apoptotic responses to IFN, double-stranded RNA and virus infection. J. Biol. Chem. 2005, 280:15561-15568.
26. van Gurp M., Festjens N., van Loo G., Saelens X., Vandenabeele P. Mitochondrial intermembrane proteins in cell death. Biochem. Biophys. Res. Commun. 2003, 304:487-497.
27. Vigil A., Park M.S., Martinez O., Chua M.A., Xiao S., Cros J.F., Martínez-Sobrido L., Woo S.L., García-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007, 67:8285-8292.
28. Wang F., Barrett J.W., Dekaban G.A., McFadden G. Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblast become immortalized. J. Virol. 2009, 83:5928-5932.
29. Wang F., Gao X., Barrett J.W., Shao Q., Bartee E., Mohamed M.R., Rahman M., Werden S., Irvine T., Gao J., Dekaban G.A., McFadden G. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 2008, 4:e1000099.
30. Wilden H., Fournier P., Zawatzky R., Schirrmacher V. Expression of RIG-I, IRF3, IFN-B and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int. J. Oncol. 2009, 34:971-982.
31. Wilden H., Schirrmacher V., Fournier P. Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. Int. J. Oncol. 2011, 39:493-504.
32. Yang D., Liu N., Zuo C., Lei S., Wu X., Zhou F., Liu C., Zhu H. Innate immune response of primary human hepatocytes with hepatitis C viral infection. PLoS One 2011, 6:e27552.
33. Yang D., Meng X., Yu Q., Xu L., Long Y., Liu B., Fang X., Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelop protein. Antimicrob. Agents Chemother. 2013, 57:4937-4944.
34. Yang D., Zuo C., Wang X., Meng X., Xue B., Liu N., Yu R., Qin Y., Gao Y., Wang Q., Hu J., Wang L., Zhou Z., Liu B., Tan D., Guang Y., Zhu H. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1264-E1273.
35. Zamarin D., Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012, 7:347-367.
36. Zaragoza C., Saura M., Padalko E.Y., Lopez-Rivera E., Lizarbe T.R., Lamas S., Lowenstein C.J. Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19051-19056.
37. Zhu H., Dong H., Eksioglu E., Hemming A., Cao M., Crawford J.M., Nelson D.R., Liu C. Hepatitis C virus triggers cell death through innate intracellular antiviral defense system. Gastroenterology 2007, 133:1649-1659.
38. Ziebarth A.J., Nowsheen S., Steg A.D., Shah M.M., Katre A.A., Dobbin Z.C., Han H.D., Lopez-Berestein G., Sood A.K., Conner M., Yang E.S., Landen C.N. Endoglin (CD105) contributes to platinum resistance and is a target for tumor- specific therapy in epithelial ovarian cancer. Clin. Cancer Res. 2013, 19:170-182.